$6.58
0.38 (+6.13%)
Elan Corp, plc (ADR) (ELN)
CAPS Rating:
The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

RSS Headlines
Fool UK
Recs
I've been following ELN for years and have been burned terribly, but each time the stock rises from the ashes to head for the stars. They have such a great success at innovative new treatments that I have to believe they will be back in the fight for the title again.